JAMA Network Home
Sign In
Perspective

HIV Status Exclusion in Sickle Cell Gene Therapy

JAMA 10.1001/jama.2026.15933

August 19, 2026 at 11:00 AM EDT

Read the full article

This Perspective discusses the ethical, scientific, clinical, and manufacturing implications of excluding patients living with HIV from gene therapies for sickle cell disease.

Corresponding Author: Lakshmanan Krishnamurti, MD, Department of Pediatrics, Yale School of Medicine, 333 Cedar St, 2073 A LMP Bldg, New Haven, CT 06510 (lakshmanan.krishnamurti@yale.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.15933?utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_term=081926

Copy to clipboard

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.

Editor's Picks